Clene reports full year 2025 results with ALS drug progress
Clene Inc. has reported a narrower net loss for 2025, totaling $26.2 million, as it advances its experimental therapy CNM‑Au8 aimed at enhancing mitochondrial health and protecting neuronal function in neurodegenerative diseases. The company’s focus remains on clinical development, with minimal revenues of $200,000 and a strategic funding boost from an oversubscribed offering that will support operations into 2027.
The significance of Clene’s progress lies in its promising data from biomarker analyses, which indicated substantial reductions in neurodegeneration markers associated with improved survival rates. With plans for a Type C meeting with the FDA and an anticipated new drug application by mid-2026, Clene is positioning itself for critical regulatory milestones that could accelerate the therapeutic landscape for conditions like ALS and multiple sclerosis.
For professionals in the longevity and healthspan research fields, Clene’s developments represent a noteworthy step toward potential breakthroughs in neurodegenerative therapies. I encourage you to explore the full details in the original article for deeper insights into this promising research.